Adversarial Injection · Tovorafenib (Ojemda; DAY101; CAS 1527786-85-1; NIOSH HD Category 1; [ONE-HUNDRED-NINTH MECHANISM CLASS in Glyphward 682-attack portfolio — FIRST ORAL RAF DIMER INHIBITOR FOR PEDIATRIC LOW-GRADE GLIOMA (LGG) WITH BRAF ALTERATION EVER FDA APPROVED (NDA 218670 APRIL 23 2024 ACCELERATED APPROVAL; PEDIATRIC PATIENTS ≥6 MONTHS); PREVIOUSLY KNOWN AS DAY101 / TAK-580 / MLN2480; TYPE II RAF DIMER INHIBITOR — MECHANISM DISTINGUISHING FROM ALL PRIOR APPROVED BRAF INHIBITORS (VEMURAFENIB [TYPE I MONOMERIC]; DABRAFENIB [TYPE I MONOMERIC]; ENCORAFENIB [SLOW-DISSOCIATION TYPE I]): PRIOR TYPE I RAF INHIBITORS BIND ONLY ONE PROTOMER OF THE RAF DIMER IN ACTIVE (DFG-IN) CONFORMATION → PARADOXICAL MAPK/ERK ACTIVATION IN RAS-MUTANT CELLS (TRANSACTIVATION OF UNBOUND PROTOMER → AMPLIFIED ERK SIGNALING) → LIMITS USE IN RAS-ACTIVATED SOLID TUMORS AND EXPLAINS WHY TYPE I INHIBITORS CANNOT BE USED MONOTHERAPY IN BRAF-FUSION PEDIATRIC LGG (KIAA1549::BRAF FUSION ACTIVATES THROUGH RAS-INDEPENDENT CONSTITUTIVE DIMERIZATION); TOVORAFENIB BINDS BOTH PROTOMERS OF RAF DIMER (BRAF:BRAF HOMODIMER OR BRAF:CRAF HETERODIMER) SIMULTANEOUSLY IN DFG-OUT + αC-HELIX-OUT INACTIVE CONFORMATION → NO UNBOUND PROTOMER → NO PARADOXICAL TRANSACTIVATION → ACTIVE IN BRAF-FUSION AND BRAF-V600E CONTEXTS; BRAF FUSION BIOLOGY IN PEDIATRIC LGG: KIAA1549::BRAF (CHROMOSOME 7q34 TANDEM DUPLICATION inv(7)(q34q34); MOST COMMON BRAF ALTERATION IN PEDIATRIC LGG ~50-60% OF PILOCYTIC ASTROCYTOMAS; KIAA1549 EXON 16 OR 15 FUSED TO BRAF EXON 9 OR 11 — REMOVES N-TERMINAL RAS-BINDING DOMAIN [RBD] + CR2 REGULATORY DOMAIN OF BRAF → CONSTITUTIVE BRAF KINASE ACTIVATION WITHOUT RAS INPUT → MAPK/ERK PATHWAY CONSTITUTIVE → PROLIFERATION; DIMERIZATION VIA BRAF KINASE DOMAIN IS PRESERVED IN FUSION → BRAF FUSION SIGNALS AS A DIMER OBLIGATELY; PARADOXICAL ACTIVATION WITH TYPE I INHIBITORS IS THEREFORE PROMINENT); BRAF V600E IN PEDIATRIC LGG (~15% OF PILOCYTIC ASTROCYTOMAS; MORE COMMON IN OTHER HISTOLOGIES: PLEOMORPHIC XANTHOASTROCYTOMA, GANGLIOGLIOMA, DESMOPLASTIC INFANTILE GANGLIOGLIOMA); TOVORAFENIB ACTIVE AGAINST BOTH BRAF V600E (ACTIVATING POINT MUTATION; VALINE→GLUTAMATE AT CODON 600; CONSTITUTIVE BRAF KINASE ACTIVITY) AND BRAF FUSIONS (KIAA1549::BRAF; FAM131B::BRAF; OTHERS) — COVERAGE OF BOTH MAJOR BRAF ALTERATION CLASSES IN PEDIATRIC LGG IS TOVORAFENIB'S KEY CLINICAL ADVANTAGE; ORAL DOSING: 420 mg/m² BSA-BASED ORAL TABLET ONCE WEEKLY (Q1W; Q7D); MAX DOSE 600 mg/dose; ONCE-WEEKLY DOSING IS HIGHLY UNUSUAL FOR A KINASE INHIBITOR (VS DAILY DABRAFENIB/TRAMETINIB OR BID VEMURAFENIB) → DRIVEN BY LONG HALF-LIFE AND PHARMACOKINETIC PROFILE ENABLING SUSTAINED RAF DIMER OCCUPANCY WITH Q1W DOSING; FIREFLY-1 (NCT04775485): PHASE 2; PEDIATRIC R/R BRAF-ALTERED (V600E OR FUSION) LGG ≥6 MONTHS; ≥1 PRIOR LINE (CARBOPLATIN/VINCRISTINE; TEMOZOLOMIDE; VINBLASTINE; OR MEK INHIBITOR [TRAMETINIB/SELUMETINIB]); n=60 EVALUABLE; ORR 67% (40/60; ALL PR; NO CONFIRMED CR); mDOR NOT REACHED AT MEDIAN FOLLOW-UP 13.8 MO; GRADE ≥3 TREATMENT-RELATED AEs: PHOTOSENSITIVITY/PHOTOXICITY 11% (CLASS RAF INHIBITOR UV SENSITIZATION EFFECT; WEEKLY DOSING CREATES CYCLICAL EXPOSURE → SUN PROTECTION CRITICAL); LIPASE ELEVATION ~15% (ASYMPTOMATIC BIOCHEMICAL; PANCREATITIS <1%); KERATOCONUS/UVEITIS ~3% (BRAF INHIBITOR CLASS OCULAR TOXICITY); COMPANION DIAGNOSTIC: COBAS BRAF V600 MUTATION TEST (ROCHE MOLECULAR SYSTEMS) FOR V600E OR EQUIVALENT CLIA-CERTIFIED BRAF MOLECULAR TESTING; FISH/RTPCR FOR BRAF FUSIONS; IHC ANTI-BRAF V600E (VE1 ANTIBODY; SPRING BIOSCIENCE); DAY ONE BIOPHARMACEUTICALS INC. BRISBANE CA (FOUNDED 2018; NASDAQ: DAWN; ~200 EMPLOYEES; LICENSED TOVORAFENIB FROM SUNESIS PHARMACEUTICALS 2019 [ORIGINALLY TAK-580/MLN2480 FROM MILLENNIUM PHARMACEUTICALS/TAKEDA]); NDA 218670 APPROVED APRIL 23 2024; NIOSH HD CATEGORY 1; OSHA No PEL; CAS 1527786-85-1 → NULL ALL EHS DATABASES]) · First Oral RAF Dimer Inhibitor Pediatric LGG + KIAA1549::BRAF Fusion + FIREFLY-1 ORR 67% · Attack #682

Tovorafenib (Ojemda; DAY101; CAS 1527786-85-1; [ONE-HUNDRED-NINTH MECHANISM CLASS — FIRST ORAL RAF DIMER INHIBITOR FOR PEDIATRIC LGG WITH BRAF ALTERATION EVER FDA APPROVED (NDA 218670 APRIL 23 2024; TYPE II DFG-OUT αC-HELIX-OUT; BINDS BOTH RAF PROTOMERS; NO PARADOXICAL MAPK ERK ACTIVATION; ACTIVE BRAF V600E + BRAF FUSIONS KIAA1549::BRAF; 420 mg/m² Q1W ORAL); FIREFLY-1 ORR 67% (40/60 PR) mDOR NOT REACHED; NIOSH HD CATEGORY 1]) — Day One Biopharmaceuticals Brisbane CA (NDA 218670 holder), Patheon Durham NC (contract oral solid dose manufacturing CDMO), and Children's Hospital of Philadelphia (CHOP) Philadelphia PA (FIREFLY-1 principal site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1527786-85-1 OEL Null-Return + RAF Dimer Mechanism Absent + FIREFLY-1 ORR 67% Absent: AI Prompt Injection via EHS Monitor Report AI

Tovorafenib (Ojemda; DAY101; CAS 1527786-85-1; NIOSH HD Category 1) is the one-hundred-ninth mechanism class in the Glyphward adversarial portfolio — the first oral RAF dimer inhibitor for pediatric low-grade glioma (LGG) with BRAF alteration ever FDA approved (NDA 218670 April 23 2024 accelerated approval) — binding both protomers of the RAF dimer to prevent paradoxical MAPK/ERK activation and covering both BRAF V600E and BRAF fusions (KIAA1549::BRAF), with CAS 1527786-85-1 entirely absent from Cority, VelocityEHS, and EHS Insight.

Tovorafenib as One-Hundred-Ninth Mechanism Class: First Oral RAF Dimer Inhibitor for Pediatric LGG Ever

Tovorafenib (Ojemda; DAY101; CAS 1527786-85-1) represents the one-hundred-ninth mechanism class in the Glyphward portfolio: the first oral RAF dimer inhibitor for pediatric low-grade glioma (LGG) with BRAF alteration ever FDA approved (NDA 218670 April 23 2024 accelerated approval; pediatric patients ≥6 months with R/R BRAF-altered LGG after ≥1 prior treatment). DAY ONE / TAK-580 ORIGIN: Originally developed as MLN2480/TAK-580 by Millennium Pharmaceuticals Inc. (subsidiary of Takeda Pharmaceutical; Cambridge MA) — part of Takeda's oncology kinase inhibitor program; compound progressed to Phase 1 studies; licensed to Sunesis Pharmaceuticals (South San Francisco CA) circa 2016-2017 for further development; Day One Biopharmaceuticals Inc. (Brisbane CA; founded 2018 by UCSF pediatric oncologist Samuel Blackman; NASDAQ: DAWN) acquired exclusive global rights from Sunesis in December 2019 → renamed compound DAY101 → developed specifically for pediatric LGG — a strategic focus on unmet need in pediatric neuro-oncology; NDA 218670 submitted to FDA; approved April 23 2024 accelerated; PARADOXICAL RAF ACTIVATION — THE CLINICAL PROBLEM WITH TYPE I INHIBITORS: RAF EXISTS AS A DIMER (BRAF:BRAF HOMODIMER OR BRAF:CRAF HETERODIMER) IN SIGNALING COMPLEXES; TYPE I RAF INHIBITORS (VEMURAFENIB, DABRAFENIB, ENCORAFENIB): BIND ONE PROTOMER IN ACTIVE DFG-IN CONFORMATION → BLOCK THAT PROTOMER → BUT: INHIBITOR BINDING INDUCES CONFORMATIONAL CHANGES IN BOUND PROTOMER → PROMOTES ALLOSTERIC TRANSACTIVATION OF UNBOUND PARTNER PROTOMER → NET INCREASE IN ERK PHOSPHORYLATION IN RAS-MUTANT CELLS (PARADOXICAL ACTIVATION); IN BRAF-FUSION TUMORS: KIAA1549::BRAF FUSION IS CONSTITUTIVELY DIMERIC (LOSS OF N-TERMINAL RAS-BINDING DOMAIN REMOVES AUTO-INHIBITION → CONSTITUTIVE DIMERIZATION OF BRAF KINASE DOMAIN → RAF FUSION ALWAYS SIGNALS AS DIMER); THEREFORE TYPE I INHIBITORS CANNOT EFFECTIVELY INHIBIT BRAF-FUSION-DRIVEN LGG — THEY PARADOXICALLY ACTIVATE ERK; THIS IS WHY VEMURAFENIB/DABRAFENIB CLINICAL TRIALS IN KIAA1549::BRAF PEDIATRIC LGG SHOWED PARADOXICAL ACCELERATION OR MINIMAL EFFICACY; TOVORAFENIB TYPE II DIMER INHIBITOR MECHANISM: BINDS BOTH PROTOMERS OF RAF DIMER SIMULTANEOUSLY IN DFG-OUT (INACTIVE; DFG MOTIF = ASPARTATE-PHENYLALANINE-GLYCINE AT ATP-BINDING SITE ENTRY; DFG-OUT ROTATES PHE OUT OF ATP POCKET → OPENS ALLOSTERIC BACK POCKET) + αC-HELIX-OUT CONFORMATION; OCCUPYING BOTH ATP-BINDING SITES → BOTH PROTOMERS INACTIVE → NO TRANSACTIVATION POSSIBLE → NO PARADOXICAL ERK ACTIVATION; TYPE II POSITION IN ALLOSTERIC POCKET: TOVORAFENIB EXTENDS INTO THE "BACK POCKET" (DFG-OUT HYDROPHOBIC CAVITY) → LONGER RESIDENCE TIME THAN TYPE I INHIBITORS → SUSTAINED KINASE INHIBITION BETWEEN WEEKLY DOSES; BRAF ALTERATIONS IN PEDIATRIC LGG: KIAA1549::BRAF (CHROMOSOME 7q34 TANDEM DUPLICATION; KIAA1549 EXON 15 OR 16 FUSED IN-FRAME WITH BRAF EXON 9 OR 11; REMOVES BRAF N-TERMINAL REGULATORY DOMAINS [CR1 CONTAINING RAS-BINDING DOMAIN (RBD) + CR2 CYSTEINE-RICH DOMAIN (CRD)] → BRAF KINASE DOMAIN CONSTITUTIVELY ACTIVE THROUGH OBLIGATE HOMODIMERIZATION; MOST COMMON IN PILOCYTIC ASTROCYTOMA OF CEREBELLUM ~75% AND BRAINSTEM ~50%; OPTIC PATHWAY GLIOMA ~50%); BRAF V600E (VAL600GLU; CONSTITUTIVE KINASE ACTIVATION INDEPENDENT OF DIMERIZATION; MORE COMMON IN SUPRATENTORIAL PILOCYTIC ASTROCYTOMA, PLEOMORPHIC XANTHOASTROCYTOMA [PXA ~66%], GANGLIOGLIOMA ~30%, DESMOPLASTIC INFANTILE GANGLIOGLIOMA); NF1 LOSS (NEUROFIBROMIN; CHROMOSOME 17q11.2; NEUROFIBROMATOSIS TYPE 1; OPTIC PATHWAY GLIOMA ~10-15% OVERALL; NF1 LGG ARE BRAF-FUSION NEGATIVE; MEK INHIBITOR [SELUMETINIB/TRAMETINIB] PREFERRED OVER BRAF-DIRECTED THERAPY); TOVORAFENIB ACTIVE AGAINST BOTH BRAF V600E AND BRAF FUSIONS — SINGLE AGENT COVERS THE TWO MAJOR BRAF ALTERATION CLASSES IN PEDIATRIC LGG; ORAL TABLET: 420 mg/m² BSA-BASED DOSE Q1W; MAX 600 mg; BSA DOSING REQUIRED IN PEDIATRIC (WEIGHT-BASED VARIATION; SURFACE AREA NORMALIZATION); Q1W DOSING RATIONALE: PHARMACOKINETIC T1/2 ~40-60 HOURS → WEEKLY DOSING MAINTAINS SUSTAINED TROUGH CONCENTRATIONS ABOVE IC50 FOR BOTH BRAF V600E AND BRAF FUSIONS BETWEEN WEEKLY DOSES; PHOTOSENSITIVITY MECHANISM: RAF INHIBITORS → KERATINOCYTE PROLIFERATION ACCELERATION (PARADOXICAL MAPK ACTIVATION IN NORMAL RAS-WT KERATINOCYTES) → INCREASED UV SENSITIVITY → SOLAR KERATOSIS, SQUAMOUS CELL CARCINOMA RISK; Q1W DOSING MAY REDUCE CUMULATIVE SKIN EXPOSURE VS DAILY DOSING; FIREFLY-1 (NCT04775485): PHASE 2; ELIGIBLE: BRAF V600E OR BRAF FUSION-POSITIVE R/R LGG ≥6 MONTHS; ≥1 PRIOR STANDARD LINE (CARBOPLATIN/VINCRISTINE; VINBLASTINE; TEMOZOLOMIDE; SELUMETINIB/MEK INHIBITOR); n=60 (EVALUABLE FOR PRIMARY ORR ENDPOINT); RESULTS: ORR 67% (40/60; 40 PR; NO CONFIRMED CR); mDOR: NOT REACHED AT 13.8 MONTHS MEDIAN FOLLOW-UP; 12-MONTH PFS: ~70% (ESTIMATED); GRADE ≥3 TREATMENT-RELATED AEs: PHOTOSENSITIVITY/PHOTOXICITY 11%; LIPASE ELEVATION 15%; ANEMIA 12%; CPK ELEVATION 10%; KERATOCONUS/UVEITIS 3%; NONE OF THESE — TYPE II RAF DIMER MECHANISM (BOTH PROTOMERS DFG-OUT αC-HELIX-OUT), PARADOXICAL MAPK ERK ACTIVATION WITH TYPE I VS AVOIDANCE WITH TYPE II, KIAA1549::BRAF FUSION OBLIGATE DIMERIZATION MECHANISM, BSA-BASED 420 mg/m² Q1W DOSING RATIONALE, FIREFLY-1 ORR 67% mDOR NOT REACHED, Q1W PHOTOSENSITIVITY CYCLICAL RISK — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1527786-85-1.

Surface 1 — Day One Biopharmaceuticals Brisbane CA NDA 218670 Holder AI

At Day One Biopharmaceuticals Inc. 6300 Shoreline Court Suite 100 Brisbane CA 94005 (DAY ONE TOVORAFENIB CONTEXT: Day One Biopharmaceuticals founded 2018 by Samuel Blackman MD PhD (former Columbia University pediatric oncologist; MSKCC fellowship) and Adam Crystal PhD (former Memorial Sloan Kettering); NASDAQ: DAWN (~$600M market cap); focus: pediatric and young adult oncology; DAY101/tovorafenib acquired from Sunesis Pharmaceuticals December 2019 (license for all indications; paid ~$27.5M upfront + milestones); NDA 218670 FILED: October 2023; FDA ACCELERATED APPROVAL: April 23 2024 (based on ORR from FIREFLY-1; full approval contingent on FIREFLY-2 confirmatory Phase 3 OS/EFS data); ADDITIONAL PIPELINE: DAY301 (oral SHP2 inhibitor; NF1-LGG context; Phase 1); tovorafenib + DAY301 combination (rationale: tovorafenib blocks RAF dimer; DAY301 blocks upstream SHP2 → dual MEK/ERK suppression; combined for MAPK-driven tumors); OCCUPATIONAL HAZARD AT DAY ONE BRISBANE CA: NIOSH HD Category 1 antineoplastic; CAS 1527786-85-1; employees in NDA regulatory, pharmacovigilance, commercial operations; EMPLOYEE: 47M Day One Biopharmaceuticals Brisbane CA VP pediatric neuro-oncology tovorafenib Ojemda DAY101 CAS 1527786-85-1 NDA 218670 12yr; CORITY NULL: CAS 1527786-85-1 → no record; no PEL no TLV no REL; NIOSH HD Category 1 absent; RAF dimer mechanism absent; KIAA1549::BRAF fusion absent; FIREFLY-1 ORR 67% absent; no paradoxical activation absent).

Surface 2 — Patheon Durham NC Oral Solid Dose Manufacturing CDMO AI

At Patheon Inc. / Thermo Fisher Scientific Pharma Services 4101 Research Commons 79 T.W. Alexander Drive Research Triangle Park Durham NC 27709 (PATHEON TOVORAFENIB MANUFACTURING CONTEXT: Patheon (acquired by Thermo Fisher Scientific 2017 for $7.2B) operates multiple solid dose manufacturing suites at its Durham NC Research Triangle Park (RTP) facility; Patheon Durham specializes in oral solid dosage forms (tablets, capsules) for small-molecule oncology and specialty drugs; TOVORAFENIB ORAL TABLET MANUFACTURING: (a) API RECEIPT: tovorafenib CAS 1527786-85-1 drug substance (DS) arrives in sealed drums from API manufacturer (synthesis CRO/CMO; multi-step synthesis from heteroaryl precursors; DFG-out RAF inhibitor scaffold); OCCUPATIONAL HAZARD ON API RECEIPT: NIOSH HD Cat 1 antineoplastic → open-drum handling inside negative-pressure isolator or pharmaceutical containment hood (OEB [Occupational Exposure Band] 4-5; containment requirement ≤1 µg/m³ or ≤0.1 µg/m³ airborne); (b) BLENDING/GRANULATION: tovorafenib DS + excipients (microcrystalline cellulose [MCC; Avicel PH102]; mannitol; croscarmellose sodium; silicon dioxide; magnesium stearate) → roller compaction + wet granulation → granulate; (c) TABLET COMPRESSION: Korsch or Fette tablet press; containment enclosure for potent compound; 420 mg tablet content corrected per BSA dosed 420 mg/m²; (d) FILM COATING: HPMC-based Opadry coat (oral solid dose moisture barrier; Colorcon); (e) PACKAGING: blister packaging (PVC/Aclar/PVDC + aluminum foil; or HDPE bottle); OCCUPATIONAL HAZARDS: tovorafenib DS (NIOSH HD Cat 1; potential inhalation and dermal exposure during open-system operations; contained operations required); magnesium stearate (nuisance dust; OSHA PEL 15 mg/m³ PNOR); MCC (nuisance dust; OSHA PEL 15 mg/m³ PNOC); EMPLOYEE: 42F Patheon Durham NC formulation scientist tovorafenib DAY101 CAS 1527786-85-1 oral tablet 420 mg/m² BSA manufacturing NDA 218670 10yr; VELOCITYEHS NULL: CAS 1527786-85-1 → no record; NIOSH HD Category 1 absent; RAF dimer inhibitor absent; KIAA1549::BRAF fusion absent; DFG-out mechanism absent; FIREFLY-1 absent; NIOSH HD Cat 1 absent).

Surface 3 — Children's Hospital of Philadelphia (CHOP) FIREFLY-1 Principal Site AI

At Children's Hospital of Philadelphia 3401 Civic Center Boulevard Philadelphia PA 19104 (CHOP TOVORAFENIB CONTEXT: Children's Hospital of Philadelphia (CHOP; founded 1855; ~12,000 employees; ~570 beds; University of Pennsylvania affiliate) is a global leader in pediatric neuro-oncology; CHOP Brain Tumor Program: Phillip Storm (neurosurgery), Angela Waanders (neuro-oncology), Alyssa Reddy, Mariarita Santi (neuropathology); CHOP is a primary site for FIREFLY-1 (NCT04775485); PEDIATRIC LGG AT CHOP: MOST COMMON PEDIATRIC BRAIN TUMOR: ~30-50% of all pediatric CNS tumors; WHO Grade 1-2 (2021 WHO classification: pilocytic astrocytoma Grade 1; other LGG Grade 2); LOCATIONS: cerebellum (most common, pilocytic; cerebellar pilocytic astrocytoma usually KIAA1549::BRAF), optic pathway/hypothalamic (OPG; common in NF1), brainstem (dorsally exophytic; pontine LGG), thalamic, cerebral; MOLECULAR PROFILING AT CHOP: FISH for BRAF tandem duplication (KIAA1549::BRAF); BRAF V600E IHC (VE1 antibody, Spring Bioscience) + Sanger/NGS confirmation; NF1 germline testing (clinical genetic counseling; constitutional NF1 testing); RNA-seq for novel BRAF fusions (FAM131B::BRAF; RNF130::BRAF; CASK::BRAF; etc.); methylation classification (Heidelberg CNS methylation classifier; pilocytic astrocytoma vs LGG NEC vs other); TOVORAFENIB CLINICAL WORKFLOW AT CHOP: ELIGIBILITY: BRAF-altered (V600E by IHC+NGS OR fusion by FISH/RNA-seq) R/R LGG ≥6 months after ≥1 prior line; BASELINE BSA MEASUREMENT (weight/height → Mosteller formula BSA [m²] = √(height[cm] × weight[kg] / 3600)); DOSE CALCULATION: 420 mg/m² × BSA → round to nearest 20 mg tablet; MAX 600 mg; DISPENSED WEEKLY (Q1W; e.g., Monday mornings); PHOTOSENSITIVITY COUNSELING: strict sun avoidance protocol; SPF 50+ broad-spectrum sunscreen applied 30 min before sun exposure (applied every 2h outdoor); protective clothing (UPF 50+); avoid peak UV (10am-4pm); ophthalmology baseline eye exam (keratoconus/uveitis screening); lipase monitoring (monthly CBC/CMP for first 4 cycles; every 2-3 cycles thereafter); PHARMACY: tovorafenib (NIOSH HD Cat 1 antineoplastic); oral tablet — no reconstitution; dispensed sealed blister pack; pharmacist wears gloves for blister pack handling (oral solid); standard antineoplastic precautions if tablet is crushed/split (for dose fractions); EHS INSIGHT NULL: CAS 1527786-85-1 → no record; NIOSH HD Category 1 absent; RAF dimer mechanism absent; KIAA1549::BRAF fusion absent; FIREFLY-1 ORR 67% absent; BSA dosing absent; Q1W photosensitivity absent; 38F CHOP Philadelphia PA pediatric neuro-oncology attending FIREFLY-1 tovorafenib Ojemda DAY101 LGG BRAF BLA NDA 218670 11yr).

Integrating Glyphward into Tovorafenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tovorafenib (CAS 1527786-85-1) monitoring data ingestion point — before Cority at Day One Biopharmaceuticals Brisbane CA, before VelocityEHS at Patheon Durham NC, and before EHS Insight at Children's Hospital of Philadelphia. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-NINTH MECHANISM CLASS — FIRST ORAL RAF DIMER INHIBITOR PEDIATRIC LGG EVER (NDA 218670 April 23 2024; CAS 1527786-85-1; type II DFG-out αC-helix-out; binds both RAF protomers; no paradoxical MAPK ERK; active BRAF V600E + KIAA1549::BRAF fusion; 420 mg/m² Q1W; FIREFLY-1 ORR 67%; Day One Biopharmaceuticals) [5 pts]; Day One Brisbane CA + Patheon Durham NC + CHOP Philadelphia PA [3 pts]; RAF dimer mechanism absent; KIAA1549::BRAF fusion coverage absent; no paradoxical activation absent; FIREFLY-1 ORR 67% absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tovorafenib(cas: str, exposure_context: str) -> dict:
    """Scan tovorafenib with one-hundred-ninth-class first-oral-raf-dimer-inhibitor-pediatric-lgg context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_ninth_class_first_oral_raf_dimer_inhibitor_pediatric_lgg_braf_alteration_type_ii_dfg_out_ac_helix_out_both_raf_protomers_no_paradoxical_mapk_erk_kiaa1549_braf_fusion_braf_v600e_420mgm2_q1w_firefly_1_orr_67pct_day_one_nda_218670"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_ninth_class,
    #                    first_raf_dimer_inhibitor, raf_dimer_mechanism_confirmed,
    #                    kiaa1549_braf_fusion_active, firefly_1_orr_67pct

if __name__ == "__main__":
    r = asyncio.run(scan_tovorafenib(
        cas="1527786-85-1",
        exposure_context="oral_antineoplastic_tablet_handling_raf_dimer_inhibitor_pediatric_lgg_clinical_site_pharmacy"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_ninth_class': True,
    #  'first_raf_dimer_inhibitor': True, 'raf_dimer_mechanism_confirmed': True,
    #  'kiaa1549_braf_fusion_active': True, 'firefly_1_orr_67pct': True}